Biotechnology

Immix Biopharma heads to Morgan Stanley's key conference. Can its promising CAR-T therapy for AL Amyloidosis convince investors to fund the final mile?

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

A strategic investment in Carolina Components Group signals a larger PE trend: fortifying the single-use technology supply chain to de-risk drug manufacturing.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

An AI-driven biodefense firm is using anti-racketeering laws to fight alleged market fraud. Is this a landmark battle for market integrity?

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

As Tecan prepares to unveil its H1 2026 results, the numbers will offer more than a corporate health check—they are a key signal for the entire lab automation industry's recovery.

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

Hidehiko Otake's promotion isn't just a corporate shuffle. It’s a bet that Corundum can turn our deepest biological data into the future of medicine.

By partnering with major CROs, Revolune is tackling a key bottleneck in advanced tissue analysis. This new ecosystem could change how labs of all sizes innovate.

Oblenio Bio's LBL-051 enters human trials, offering hope for a true "immune reset" and drug-free remission for severe autoimmune disease patients.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

A strategic delegation of 15 AI startups signals a new era. Taipei is not just selling tech; it's building a deep innovation ecosystem with Japan.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

Pathos AI leverages its Foundry platform to ink a $2.2B deal with Alphamab for a novel cancer drug, signaling a new era of AI-led pharma strategy.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

Gene Solutions’ academy in Malaysia signals a shift from complex genomic data to empowering clinicians with actionable insights for a new era of cancer care.

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.